ClinicalTrials.gg
TerminatedNCT04769453MAGICUpdated Mar 15, 2023

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

An interventional study of Canaloplasty using the iTrack microcatheter with Healon GV Pro and Canaloplasty using the Omni surgical system with Healon GV Pro in Primary Open Angle Glaucoma, sponsored by Nova Eye, Inc.. Terminated at 7 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Nova Eye, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor-initiated, suspension of study due to modification of key parameters.

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
242nd of 279
20 · median 84
Started
2021
with 17 others
No phase
82 of 348
14 open now
Registered
254th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 242nd largest by enrollment of the 279 interventional ones that give a count, is one of 18 that started in 2021, is one of 82 with no phase, and was the 254th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

A prospective, multicenter, randomized, single-masked clinical trial to evaluate the effectiveness outcomes of canaloplasty performed as a standalone procedure with the iTrack microcatheter to the Omni surgical system, and to compare the effectiveness of two types of Ophthalmic Viscoelastic Device (OVD).

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

Keywords

  • Canaloplasty
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with mild to moderate open angle Glaucoma.
  2. Visual Field test (Humphrey SITA standard 24-2) with mean deviation better than or equal to -12.0 dB
  3. IOP \< or = to 36 mmHG while on one to four ocular hypotensive medications
  4. Shaffer grade of > or = III in all four quadrants
  5. Able and willing to comply with the Protocol and follow up visits for 12 months

Exclusion criteria

Exclusion Criteria:

  1. Laser trabeculoplasty other than selective laser trabeculoplasty (SLT)
  2. History of iStent or iStent inject within 180 days of the screening visit
  3. History of ECP or Micropulse laser
  4. Trabeculectomy or other bleb forming procedure including Xen, Express and glaucoma drainage device/valves
  5. Prior canaloplasty (ab interno and ab externo)
  6. Prior goniotomy or trabeculotomy
  7. History of Hydrus microstent or suprachoroidal stent
  8. History of cataract surgery within 6 months of screening
  9. Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma, pigmentary or pseudoexfoliative glaucoma
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    iTrack canaloplasty microcatheter with Healon GV Pro

    Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)

    Device: Canaloplasty using the iTrack microcatheter with Healon GV Pro

  • Active comparator
    OMNI surgical system with Healon GV Pro

    Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon GV Pro (ophthalmic viscoelastic device)

    Device: Canaloplasty using the Omni surgical system with Healon GV Pro

  • Active comparator
    iTrack canaloplasty microcatheter with Healon Pro

    Patients will be randomized to the iTrack microcatheter (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)

    Device: Canaloplasty using the iTrack microcatheter with Healon Pro

  • Active comparator
    OMNI surgical system with Healon Pro

    Patients will be randomized to the OMNI surgical system (canaloplasty) with Healon Pro (ophthalmic viscoelastic device)

    Device: Canaloplasty using the Omni surgical system with Healon Pro

Interventions

  • DeviceCanaloplasty using the iTrack microcatheter with Healon GV Pro

    360 degree microcatheterization and viscodilation of Schlemm's canal

  • DeviceCanaloplasty using the Omni surgical system with Healon GV Pro

    360 degree microcatheterization and viscodilation of Schlemm's canal

  • DeviceCanaloplasty using the iTrack microcatheter with Healon Pro

    360 degree microcatheterization and viscodilation of Schlemm's canal

  • DeviceCanaloplasty using the Omni surgical system with Healon Pro

    360 degree microcatheterization and viscodilation of Schlemm's canal

06

What researchers measure

Primary outcomes

  1. Reduction in mean Intraocular pressure (IOP) and glaucoma medication use at 12 months post-intervention

    IOP will be measured at each study visit using Goldmann applanation tonometry

    Time frame: 12 months

Secondary outcomes

  1. Complications intra-operatively and post-operatively associated with the iTrack canaloplasty microcatheter compared to complications intra-operatively and post-operatively with the OMNI surgical system.

    Time frame: 12 months

  2. Visual acuity at 12 months compared to baseline visual acuity

    Best corrected visual acuity (BCVA) will be assessed using the standard Snellen eye chart

    Time frame: 12 months

07

Study locations

7 sites
  • Arizona Advanced Eye Research Institute
    Glendale, Arizona 85306, United States
  • Beverly Hills Institute of Ophthalmology
    Beverly Hills, California 90210, United States
  • Coastal Vision
    Orange, California 92868, United States
  • Dean McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Cataract and Laser Institute of Southern Oregon
    Medford, Oregon 97501, United States
  • El Paso Eye Surgeons
    El Paso, Texas 79902, United States
  • Eye Centers of Racine and Kenosha
    Kenosha, Wisconsin 53142, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jan 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 24, 2021
StartActual
Apr 29, 2021
Primary completionActual
Jan 26, 2023
CompletionActual
Jan 26, 2023
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04769453
Lead sponsor
Nova Eye, Inc.
Responsible party
Sponsor
First posted
Feb 24, 2021
Start date
Apr 29, 2021
Primary completion
Jan 26, 2023
Completion
Jan 26, 2023
Last update
Mar 15, 2023

Study contacts

Shamil Patel, MD, MBA
principal investigator · Eye Physicians and Surgeons of Arizona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion